ETF MANAGERS GROUP, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
ETF MANAGERS GROUP, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$477,894
+15.4%
318,596
-10.0%
0.02%
-21.1%
Q4 2022$414,169
+11.0%
353,991
+7.3%
0.02%
+58.3%
Q3 2022$373,000
-24.0%
329,826
+8.2%
0.01%
-14.3%
Q2 2022$491,000
+69.9%
304,934
+58.3%
0.01%
+133.3%
Q1 2022$289,000
-44.3%
192,627
-7.3%
0.01%
-40.0%
Q4 2021$519,000207,7350.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders